# NCT05756569 (NCT05756569)

> Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05756569
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Emory University
- Conditions: Bladder Squamous Cell Carcinoma; Locally Advanced Bladder Carcinoma; Malignant Renal Pelvis Neoplasm; Malignant Ureter Neoplasm; Malignant Urethral Neoplasm; Metastatic Bladder Carcinoma; Stage III Bladder Cancer AJCC v8; Stage IV Bladder Cancer AJCC v8; Unresectable Bladder Carcinoma; Urachal Adenocarcinoma; Bladder Adenocarcinoma
- Interventions: Biospecimen Collection; Computed Tomography; Enfortumab Vedotin; Magnetic Resonance Imaging; Pembrolizumab; Questionnaire Administration
- Enrollment: 25
- Primary outcome: Overall response rate

## Indexed commentary on NCT05756569 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05756569